ClinicalTrials.gg
CompletedNCT01685983Updated Mar 15, 2019Results posted

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

A Phase 2 interventional study of Abiraterone acetate and Prednisolone in Prostate Cancer, sponsored by Janssen Research & Development, LLC. Completed at 9 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Aug 2011, registered Sep 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
33rd of 98
82 · median 56
Started
2011
with 4 others
Phase 2
59 of 98
9 open now
Registered
23rd of 98
by date
Lead sponsor
13 of 98
Janssen Research & Development, LLC

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 33rd largest by enrollment, is one of 5 that started in 2011, is one of 59 in phase 2, and was the 23rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy in Korea or Taiwan of oral abiraterone acetate and oral prednisolone in men with metastatic-castration resistant prostate cancer (mCRPC) and with disease progression following treatment with a docetaxel-containing chemotherapy.

Read the detailed description

This is an open-label (all people know the identity of the intervention), multicenter, single arm (only one treatment group) study to evaluate the efficacy and safety of abiraterone acetate in patients with mCRPC. The study will be divided into screening phase (up to 28 days before enrollment), treatment phase including treatment cycles (each cycle of treatment will be 28 days), and follow-up phase. Approximately 80 patients will be enrolled into this study. Safety evaluations for adverse events, clinical laboratory tests, electrocardiogram and vital signs as well as pharmacokinetic (what the body does to drug) assessments will be conducted in this study. Patients will continue to receive abiraterone acetate plus prednisolone until disease progression or occurrence of unacceptable toxicity.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Metastatic-castration resistant prostate cancer
  • Prostate specific antigen
  • Abiraterone acetate
  • JNJ-212082
  • Abiraterone
  • Prednisolone
  • Androgen Deprivation
  • Docetaxel-based chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate (stage IV)
  • Has documented Prostate Specific Antigen (PSA) progression according to protocol-specific prostate specific antigen working group (PSAWG) eligibility criteria
  • Has undergone prior chemotherapy for prostate cancer with regimen(s) containing Docetaxel
  • Has an ongoing androgen deprivation with serum testosterone less than 50 ng/dL
  • Has not received radiotherapy, chemotherapy, or immunotherapy at least 30 days prior to the treatment
  • Performance Status less than or equal to 2

Exclusion criteria

Exclusion Criteria:

  • Active or uncontrolled disease that may require therapy
  • Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
  • Uncontrolled hypertension
  • less than or equal to 9.0 g/dL independent of transfusion
  • Has abnormal liver function tests
  • Surgery or local prostatic intervention within 30 days of the first dose
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Abiraterone actetate and Prednisolone

    Drug: Abiraterone acetate · Drug: Prednisolone

Interventions

  • Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.

    Also known as: JNJ-212082

  • Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Prostate-specific Antigen (PSA) Response

    The PSA response was evaluated according to Prostate-Specific Antigen Working Group (PSAWG) criterion, which is, greater than or equal to 50 percent decrease in PSA from Baseline during the study, which would be subsequently confirmed by a measurement that is at least 4 or more weeks after initial documentation of PSA response.

    Time frame: Baseline, Month 4

Secondary outcomes

  1. Overall Survival

    Overall survival is defined as the time interval from the date of the first dose to the date of death due to any reason.

    Time frame: Up to 3 Years

  2. Time to PSA Progression

    Time to PSA progression was measured as the time interval from the date of the first dose to the date of PSA progression as defined in the protocol-specific PSAWG criteria. For participants who have achieved a greater than or equal to (\>=) 50% decrease from the baseline PSA, assessment of time to disease progression is when the PSA has increased 50% above the nadir and at a minimum of 5 nanogram/mililiter (ng/mL). For participants without a PSA decrease of this magnitude or without a decrease, the time for progression is calculated at the time a 25% increase from baseline PSA has been achieved.

    Time frame: Up to 28 Months

  3. Percentage of Participants With Objective Radiographic Response

    Percentage of participants with radiographic objective response is defined as the percentage of participants with complete response (CR) or partial response (PR) as best overall response based on reconciled radiographic disease assessment according to RECIST Version 1.0. The CR is disappearance of all lesions. The PR is at least 30 percent decrease in sum of the longest diameter of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

    Time frame: Up to 3 Years

  4. Serum Testosterone

    Median serum testosterone concentration was reported at baseline and End-of-Treatment visit.

    Time frame: Baseline and End-of-Treatment Visit (up to approximately 3 years)

  5. Dehydroepiandrosterone Sulfate (DHEA-S)

    Median DHEA-S concentration was reported at baseline and End-of-Treatment visit.

    Time frame: Baseline and End-of-Treatment Visit (up to approximately 3 years)

  6. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Up to 3 Years

07

Results

Posted May 23, 2016

Participant flow

Participant flow — Overall Study
MilestoneAbiraterone Acetate
Started82
Completed0
Not completed82
Withdrew: Adverse event7
Withdrew: Death1
Withdrew: Withdrawal by subject19
Withdrew: Protocol violation2
Withdrew: Physician decision13
Withdrew: Other7
Withdrew: Progressive disease32
Withdrew: Noncompliance with study drug1

Outcome measures

SecondaryOverall Survival

Overall survival is defined as the time interval from the date of the first dose to the date of death due to any reason.

Time frame:
Up to 3 Years
Reported as:
Median · Days
Overall Survival
DaysAbiraterone Acetate and Prednisolone
Overall Survival538 (358.0 to 660.0)
SecondaryTime to PSA Progression

Time to PSA progression was measured as the time interval from the date of the first dose to the date of PSA progression as defined in the protocol-specific PSAWG criteria. For participants who have achieved a greater than or equal to (\>=) 50% decrease from the baseline PSA, assessment of time to disease progression is when the PSA has increased 50% above the nadir and at a minimum of 5 nanogram/mililiter (ng/mL). For participants without a PSA decrease of this magnitude or without a decrease, the time for progression is calculated at the time a 25% increase from baseline PSA has been achieved.

Time frame:
Up to 28 Months
Reported as:
Median · Days
Time to PSA Progression
DaysAbiraterone Acetate and Prednisolone
Time to PSA Progression141 (112.0 to 170.0)
SecondaryPercentage of Participants With Objective Radiographic Response

Percentage of participants with radiographic objective response is defined as the percentage of participants with complete response (CR) or partial response (PR) as best overall response based on reconciled radiographic disease assessment according to RECIST Version 1.0. The CR is disappearance of all lesions. The PR is at least 30 percent decrease in sum of the longest diameter of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.

Time frame:
Up to 3 Years
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Radiographic Response
Percentage of participantsAbiraterone Acetate and Prednisolone
Percentage of Participants With Objective Radiographic Response6.1
SecondarySerum Testosterone

Median serum testosterone concentration was reported at baseline and End-of-Treatment visit.

Time frame:
Baseline and End-of-Treatment Visit (up to approximately 3 years)
Reported as:
Median · nanomole per liter
Serum Testosterone
nanomole per literAbiraterone Acetate and Prednisolone
Baseline1.210 (1.21 to 5.02)
End-of-Treatment Visit1.210 (1.21 to 1.79)
SecondaryDehydroepiandrosterone Sulfate (DHEA-S)

Median DHEA-S concentration was reported at baseline and End-of-Treatment visit.

Time frame:
Baseline and End-of-Treatment Visit (up to approximately 3 years)
Reported as:
Median · micromole per liter
Dehydroepiandrosterone Sulfate (DHEA-S)
micromole per literAbiraterone Acetate and Prednisolone
Baseline0.725 (0.08 to 6.28)
End-of-Treatment Visit0.080 (0.08 to 0.20)
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Up to 3 Years
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsAbiraterone Acetate and Prednisolone
AEs81
SAEs40
PrimaryPercentage of Participants With Prostate-specific Antigen (PSA) Response

The PSA response was evaluated according to Prostate-Specific Antigen Working Group (PSAWG) criterion, which is, greater than or equal to 50 percent decrease in PSA from Baseline during the study, which would be subsequently confirmed by a measurement that is at least 4 or more weeks after initial documentation of PSA response.

Time frame:
Baseline, Month 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Prostate-specific Antigen (PSA) Response
Percentage of participantsAbiraterone Acetate and Prednisolone
Percentage of Participants With Prostate-specific Antigen (PSA) Response42.7

Adverse events

Collected over Approximately 3 Years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abiraterone Acetate—40/82 (48.8%)73/82 (89%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventAbiraterone Acetate
AnaemiaBlood and lymphatic system disorders3/82
VomitingGastrointestinal disorders3/82
AstheniaGeneral disorders3/82
Bone painMusculoskeletal and connective tissue disorders3/82
Abdominal painGastrointestinal disorders2/82
NauseaGastrointestinal disorders2/82
PyrexiaGeneral disorders2/82
CellulitisInfections and infestations2/82
Spinal compression fractureInjury, poisoning and procedural complications2/82
Decreased appetiteMetabolism and nutrition disorders2/82
Most frequent other events
Showing 10 of 38
Most frequent other events
EventAbiraterone Acetate
Bone painMusculoskeletal and connective tissue disorders21/82
Back painMusculoskeletal and connective tissue disorders19/82
NauseaGastrointestinal disorders18/82
HypokalaemiaMetabolism and nutrition disorders15/82
HypertensionVascular disorders15/82
ConstipationGastrointestinal disorders14/82
VomitingGastrointestinal disorders14/82
Musculoskeletal painMusculoskeletal and connective tissue disorders13/82
Oedema peripheralGeneral disorders12/82
Pain in extremityMusculoskeletal and connective tissue disorders12/82

Baseline characteristics

Age, Continuous
Age, Continuous(years)Abiraterone Acetate
Mean71 ± 7.35
Sex: Female, Male
Sex: Female, Male(Participants)Abiraterone Acetate
Female0
Male82
Region of Enrollment
Region of Enrollment(Participants)Abiraterone Acetate
Korea, Republic Of52
Taiwan, Province Of China30
08

Study locations

9 sites
  • Busan, Korea, Republic of
  • Cheongju-Si, Korea, Republic of
  • Seongnam-Si, Gyeonggi-Do, Korea, Republic of
  • Seoul, Korea, Republic of
  • Kaohsiung, Taiwan
  • Taichung City, Taiwan
  • Taichung, Taiwan
  • Taipei, Taiwan
  • Taoyuan County, Taiwan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2011 to primary completion in Jan 2013, 16 months.

Results were first posted in May 2016, 3 years 3 months after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 16 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2012
First posted
Sep 17, 2012
StartActual
Aug 30, 2011
Primary completionActual
Jan 24, 2013
CompletionActual
Mar 6, 2018
Results first posted
May 23, 2016
Last update
Mar 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01685983
Responsible party
Sponsor
First posted
Sep 17, 2012
Start date
Aug 30, 2011
Primary completion
Jan 24, 2013
Completion
Mar 6, 2018
Results posted
May 23, 2016
Last update
Mar 15, 2019

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone Acetate · Prednisolone

Start the discussion